ACTA NEUROPHARMACOLOGICA

ACTA NEUROPHARMACOLOGICA››2021,Vol. 11››Issue (2): 32-38.DOI:10.3969/j.issn.2095-1396.2021.02.007

Previous ArticlesNext Articles

Research Progress of Anti-inflammatory Activity of PPARs Agonist in the Treatment of Depression

LIAO Yu-mei，XUE Ya-dong，CHEN Sheng, et al

  1. 1 Department of Pharmacology，College of Pharmacy，Harbin Medical University，Harbin，150081，China

    2 Department of Anatomy and Embryo，Basic Medical College，Heilongjiang University of Traditional Chinese

    Medicine，Harbin，150040，China

  • Online:2021-04-26Published:2021-04-26
  • Contact:班涛，男，药学院药理学教授，博士研究生导师；E-mail：bantao2000@163.com
  • About author:廖玉梅，女，2016 级临床药学本科生；E-mail：2539572752@qq.com
  • Supported by:
    国家自然科学基金项目（ No.82070312 、 No.31400983 ），黑龙江省自然科学基金项目（ No.H2018011 、 No.QC2018116 ），黑龙江 省博士后科研启动基金项目（ No.LBH-Q19155 ），哈尔滨医科大学药学院优秀青年基金项目（ No.2019-YQ-01 ）

PDF (PC)

3

Abstract:

The occurrence of depression is usually accompanied by the appearance of inflammation. The levels of inflammatory factors such as IL-6 and TNF-αwere significantly

increased in patients with depression，indicating that there is an important link between inflammation and the development of depression. PPARs play an important role in inhibiting inflammatory responses by interfering with NF-κB，MAPKs，STAT-1，activator protein 1，nuclear factor of activated T cells and other signaling pathways. PPARs agonists such as WY-14643，GW0742，and pioglitazone have potential antidepressant effects. The research direction of PPARs as a new target for anti-inflammatory treatment of depression is the main content of this review.

Key words:

font-family:Times,"> PPARs agonistfont-family:Helvetica,">,inflammation factorsfont-family:Helvetica,">,depression

CLC Number:

Baidu
map